文献速递其他结缔组织病

贝利尤单抗治疗成人特发性炎症性肌病

Belimumab treatment of adult idiopathic inflammatory myopathy.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

这项为期40周的多中心随机双盲安慰剂对照试验评估在标准治疗基础上加用贝利尤单抗治疗难治性特发性炎症性肌病,17例随机分组,15例纳入意向性分析,主要终点未达到,两组临床缓解率无统计学显著差异,未发现新的安全性信号,贝利尤单抗诱导初始B细胞耗竭并增加记忆B细胞数量与频率。

要点

  • 贝利尤单抗组与安慰剂组达到TIS≥40的比例为55.5% vs 33.3%,差异无统计学意义。
  • 贝利尤单抗组与安慰剂组达到DOI的比例为33.3% vs 16.7%,差异无统计学意义。
  • 贝利尤单抗组2例在第40周后达到主要缓解(TIS=72.5),安慰剂组0例。

核心结论

  • 研究未达到主要终点,两组临床缓解无统计学显著差异;贝利尤单抗组更多患者达到持续TIS≥40并达到DOI;多数接受贝利尤单抗超过40周的患者有临床改善;B细胞亚群表型变化与临床缓解无关。

研究设计与样本

  • 40周多中心、随机、双盲、安慰剂对照试验,按1:1随机接受静脉贝利尤单抗10 mg/kg或安慰剂,并设24周开放标签延伸期。
  • 共17例患者随机分组,其中15例接受贝利尤单抗或安慰剂至少5剂并纳入意向性分析。
  • 在随机分组前、第24周和第60-64周对可用样本进行流式细胞术分析;采用描述性统计、t检验、Fisher精确检验和方差分析。

主要发现

  • 第40周和第64周时,贝利尤单抗组与安慰剂组达到TIS≥40的比例为55.5% vs 33.3%(P=无统计学意义),达到DOI的比例为33.3% vs 16.7%(P=无统计学意义),两组平均TIS相似。
  • 贝利尤单抗组2例在第40周后达到主要缓解(TIS=72.5),安慰剂组0例。
  • 安慰剂组在转换为开放标签阶段后未观察到改善;无激素节约效应;未检测到新的安全性信号。
  • 贝利尤单抗未减少总B细胞,但诱导初始B细胞耗竭,同时增加记忆B细胞的数量和频率。

关键数值与推荐

  • 临床缓解采用改善定义(DOI)和总改善评分(TIS)评估。
  • 主要终点未达到,两组临床缓解无统计学显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 共17例患者随机分组,其中15例纳入意向性分析。
  • 研究未达到主要终点。
  • 两组临床缓解无统计学显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). METHODS: We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV belimumab 10 mg/kg or placebo randomization and a 24-week open-label extension. Clinical responses were measured by the definition of improvement (DOI) and total improvement score (TIS). Flow cytometry analyses were performed on available samples before randomization, at 24 and 60-64 weeks. Descriptive statistics, t-test, Fisher's exact test and analysis of variance tests were used. RESULTS: A total of 17 patients were randomized, 15 received five or more doses of belimumab or placebo and were included in the intention-to-treat analysis. More belimumab patients vs placebo attained a TIS ≥40 [55.5% vs 33.3%; P = non-significant (NS)] and achieved the DOI (33.3% vs 16.7%; P = NS) at weeks 40 and 64; the mean TIS was similar among groups. Two patients achieved major responses (TIS = 72.5) after week 40 in the belimumab arm and none in the placebo arm. No improvement in the placebo arm after switching to the open-label phase was observed. There was no steroid-sparing effect. No new safety signals were detected. Although total B cells were not reduced, belimumab induced naïve B cell depletion while enhancing the number and frequency memory B cells. CONCLUSION: The study did not meet the primary endpoint and no statistically significant differences were observed in clinical responses between arms. More patients achieved sustained TIS ≥40 and reached the DOI. Most patients who received belimumab for >40 weeks had clinical improvement. Phenotypic changes in B cell populations were not associated with clinical responses. CLINICAL TRIAL REGISTRATION NUMBER: Clinicaltrials.gov (https://clinicaltrials.gov/), NCT02347891.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Marder G, Quach T, Chadha P, et al. Belimumab treatment of adult idiopathic inflammatory myopathy. Rheumatology (Oxford). 2024. PMID: 37326854. doi:10.1093/rheumatology/kead281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。